Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... --Research and Markets , ... announced the addition of the "Cardiac Guidewires - ... offering. Global Guidewires sector is projected to reach ... accounts for nearly 35% (2015) of the ... approximately 25% (2018). Asia-Pacific is ...
(Date:12/15/2014)... Dec. 15, 2014  Colorado and Washington State ... adult use of cannabis. Oregon , ... ended prohibition during the November 2014 elections. ... http://photos.prnewswire.com/prnh/20141212/164153LOGO The benefits of legalizing ... obvious benefits like the increased tax revenue for state and ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... LLC, a leading developer of stereotactic radiosurgery and ... newest CyberKnife cancer center, which will begin treating ... Developed through a partnership between Accelitech, physicians and ... of Chicago will provide state-of-the-art CyberKnife treatment to ...
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... President and Chief Executive Officer, will provide an overview ... RBC Capital Markets, Healthcare Conference on Tuesday, February 28, ... York Palace in New York, New York.  The presentation ...
Cached Medicine Technology:Accelitech to Open the First CyberKnife Cancer Center Within the City of Chicago 2
(Date:12/15/2014)... Cancer researchers have just published an ... of deadly malignant pleural mesothelioma. Surviving Mesothelioma has just ... Click here to read it now. , ... Center, and New York’s Langone Medical Center performed complete ... in an effort to pinpoint the genes that ...
(Date:12/15/2014)... Beach, FL (PRWEB) December 15, 2014 South ... , knows that holidays can be a daze of hassle, ... slips and falls while decking halls, to burns when making ... of holiday hazards that can happen at any time. To ... pain, MD Now has made a list of helpful and ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 The increase in ... one of the main factors which is contributing to the ... for the diagnosis and treatment of hearing loss and balance ... of three parts - microphone, speaker and amplifier. The global ... rate of 6.01% during the period from 2014 to 2019. ...
(Date:12/15/2014)... 2014 In support of high-quality ... to restrictive state laws that may have unintended ... important area of public health policy. , The ... Integrity of Independent Review, contends that state legislation ... peer review determinations can result in subpar outcomes ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... believe that hair loss for,both men and women is a ... approach to help our clients that worked unlike many potions,lotions ... Revage 670(TM),because it is the only true hair regeneration laser ... by Harvard Medical, Northwestern,University , Mass General, etc.). ...
... 15 The Musculoskeletal Transplant,Foundation (MTF) announced today ... the,development phase in its efforts to develop a ... Orthofix International N.V. (Nasdaq:, OFIX ). ... package to Orthofix,which confirms the relative superiority of ...
... Inc.,(NYSE: DVA ), today announced that it ... Services, Office of Inspector General ("OIG") to respond to ... civil,investigation by the Department of Justice and the U.S. ... in the Company,s,Quarterly Report on 10-Q for the period ...
... 15 Hundreds of Aflac agents and,employees will be ... swabbed,as part of a new company initiative to boost the rolls ... program kicks off at the company,s annual,national sales conference on December ... bone marrow registration effort was inspired by Steve Karas, an Aflac,regional ...
... fighting infection than during the day, study says , , MONDAY, ... does a sick body good, new research says. , Stanford ... fights invading bacteria the hardest at night and the least ... at the American Society for Cell Biology annual meeting, in ...
... sharper young drivers, study suggests , , MONDAY, Dec. 15 (HealthDay ... the school day a bit later may lower their odds ... , The researchers found a 16.5 percent drop in auto ... the start of classes from 7:30 a.m. to 8:30 a.m. ...
Cached Medicine News:Health News:Musculoskeletal Transplant Foundation Announces Major Development Milestone in Stem Cell Allograft Product 2Health News:Musculoskeletal Transplant Foundation Announces Major Development Milestone in Stem Cell Allograft Product 3Health News:DaVita Inc. Announces Receipt of DOJ Subpoena in Connection with Previously Reported Investigation 2Health News:Aflac Agents and Employees Boost Bone Marrow Registry 2Health News:Aflac Agents and Employees Boost Bone Marrow Registry 3Health News:Immune System Works Better at Night 2Health News:Later School Start Time Cuts Teens' Car Crash Risk 2Health News:Later School Start Time Cuts Teens' Car Crash Risk 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: